Sharif N A, Xu S X, Williams G W, Crider J Y, Griffin B W, Davis T L
Molecular Pharmacology Unit, Alcon Laboratories Inc., Fort Worth, Texas 76134-2099, USA.
J Pharmacol Exp Ther. 1998 Aug;286(2):1094-102.
Specific binding of [3H]prostaglandin (PG) E1, [3H]PGE2 and [3H]PGF2alpha to washed total particulate homogenates of bovine corpus luteum comprised 60 to 82% of total binding. Scatchard analysis of competition data revealed the presence of an apparent single population of binding sites for [3H]PGE1 and [3H]PGE2 with dissociation constants (Kds) of 2.76 to 3.39 nM and apparent receptor density (Bmax) of 1.5 to 1.56 pmol/g wet weight (n = 3-4). However, [3H]PGF2alpha appeared to interact with two classes/states of binding sites (Kd1 = 6.51 +/- 0.65 nM, Bmax1 = 2.33 +/- 0.26 pmol/g wet weight; Kd2 = 986 +/- 269 nM; Bmax2 = 44.8 +/- 11.3 pmol/g wet weight, n = 11). Specific [3H]PGE1 and [3H]PGE2 binding was most potently (nanomolar affinity) inhibited by PGs with high selectivity for the EP3 receptor subtype (e.g., GR63799, sulprostone, enprostil) but was weakly (Kis > 1 microM) influenced by EP1-selective (SC-19220), FP-selective (fluprostenol, PHXA85), DP-selective (BWA868C; ZK118182), IP-selective (iloprost) and TP-selective (U46619) PGs. Specific [3H]PGF2alpha binding was potently displaced by FP-selective agents such as fluprostenol, PHXA85 and cloprostenol with nanomolar affinities (n = 3-25), but weakly (Kis > 1 microM) by other PGs showing high selectivity for other PG receptor subtypes mentioned above. The relative specificities and potencies of EP3- and FP-selective PGs tested in the binding assays were confirmed using various functional assays. These studies have provided strong pharmacological evidence for the similarity of [3H]PGE1 and [3H]PGE2 binding to EP3 receptors and for [3H]PGF2alpha binding to FP receptors in washed bovine corpus luteum homogenates.
[3H]前列腺素(PG)E1、[3H]PGE2和[3H]PGF2α与牛黄体洗涤后的总微粒体匀浆的特异性结合占总结合量的60%至82%。对竞争数据的Scatchard分析显示,[3H]PGE1和[3H]PGE2存在明显单一的结合位点群体,解离常数(Kds)为2.76至3.39 nM,表观受体密度(Bmax)为1.5至1.56 pmol/g湿重(n = 3 - 4)。然而,[3H]PGF2α似乎与两类/两种状态的结合位点相互作用(Kd1 = 6.51 ± 0.65 nM,Bmax1 = 2.33 ± 0.26 pmol/g湿重;Kd2 = 986 ± 269 nM;Bmax2 = 44.8 ± 11.3 pmol/g湿重,n = 11)。特异性[3H]PGE1和[3H]PGE2结合最有效地(纳摩尔亲和力)被对EP3受体亚型具有高选择性的PGs(例如GR63799、舒前列素、恩前列素)抑制,但受到EP1选择性(SC - 19220)、FP选择性(氟前列醇、PHXA85)、DP选择性(BWA868C;ZK118182)、IP选择性(伊洛前列素)和TP选择性(U46619)PGs的微弱影响(Kis > 1 μM)。特异性[3H]PGF2α结合被FP选择性试剂如氟前列醇、PHXA85和氯前列醇以纳摩尔亲和力有效取代(n = 3 - 25),但被对上述其他PG受体亚型具有高选择性的其他PGs微弱取代(Kis > 1 μM)。在结合试验中测试的EP3和FP选择性PGs的相对特异性和效力在各种功能试验中得到了证实。这些研究为[3H]PGE1和[3H]PGE2与EP3受体结合以及[3H]PGF2α与洗涤后的牛黄体匀浆中的FP受体结合的相似性提供了有力的药理学证据。